# PFO Closure for the Management of Migraine and Stroke

Sun U. Kwon
Department of Neurology,
Asan Medical Center, UUMC

#### **Contents**

- PFO & Migraine
  - PFO causes Migraine or Not?
  - PFO closure for Migraine
- PFO & Stroke
  - PFO as a Cause of Ischemic Stroke
  - Benefit of PFO Closure for Ischemic Stroke

#### **Hot News**

#### **Interventional Cardiology**

#### Migraine Intervention With STARFlex Technology (MIST) Trial

A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache


Conclusions—This trial confirmed the high prevalence of right-to-left shunts in patients with migraine with aura. Although no significant effect was found for primary or secondary end points, the exploratory analysis supports further investigation. The robust design of this study has served as the model for larger trials that are currently underway in the United States and Europe. (Circulation. 2008;117:1397-1404.)

### Migraine & Stroke

- Etminan M. et al (BMJ 2005:330:63)
  - Meta-analysis of 11 case-control and 3 cohort studies
- RR of ischemic stroke
  - 1.8 in migraine without aura
  - 2.3 in migraine with aura
  - 8.7 in women with migraine + oral contraceptive pill

#### Silent Brain Lesions in Migraineurs

F/50, 10 year history of Migraine



# Migraine as a Risk Factor for Subclinical Brain Lesions

from the Genetic Epidemiology of Migraine (GEM) study, a population-based survey of Dutch adults aged 20 to 60 years

| MRI outcome                                 | Control<br>(n=140) | Migraine<br>(n=295) | Migraine<br>without aura<br>(n=134) | Migraine with<br>aura<br>(n=161) |
|---|--------------------|---------------------|-------------------------------------|----------------------------------|
| Any location<br>Pt with ≥1 Brain            | 7(5.0%)            | 24 (8.1%)           | 9 (6.7%)                            | 15 (9.3%)                        |
| No of infarcts                              | 9                  | 51                  | 19                                  | 32                               |
| Posterior circulation Pt with brain infarct | 1(0.7%)            | 16(5.4%)            | 3(2.2.%)                            | 13(8.1%)                         |
| No of infarcts                              | 1                  | 33                  | 8                                   | 25                               |

#### **PFO** is More Prevalent in Migraineurs

| Subjects | RLS +<br>At rest | RLS + only<br>valsalva | total       | RR (95% CI)   |
|----------|------------------|------------------------|-------------|---------------|
| Normal   | 4/50 (8%)        | 4/50 (8%)              | 8/50 (16%)  | 2 2 (4 4 7 2) |
| Migraine | 9/44 (20.5%)     | 9/44 (20.5%)           | 18/44 (41%) | 3.2 (1.4-7.2) |

RLS; right to left shunt on TCD

#### **Prevalence of PFO in Migraineurs**

| Patient               | PFO + (%)    | RR (95% CI)      | P-value |
|-----------------------|--------------|------------------|---------|
| Migraine with aura    | 54/113 (48%) | 3.32 (1.74-6.34) | 0.003   |
| Migraine without aura | 12/53(23%)   | 1.17 (0.32-4.45) | 0.07    |
| Control               | 5(25%)       |                  |         |

Presence of PFO; assessed by TCD

### Migraine & PFO

- PFO; well-known source of paradoxical embolism
- Higher prevalence of PFO in migraine
- PFO may cause ischemic stroke and silent brain lesions in migraineurs

# Migraine-PFO Connection is Independent of Sex


| Sex           | Diagnosis | Overall RLS prevalence | Grade 2 RLS prevalence |
|---------------|-----------|------------------------|------------------------|
| Females       | MA+       | 60/123 (48.8)          | 31/123 (25.5)          |
| Males         | MA+       | 12/32 (37.5)           | 4/32 (12.5)            |
| Females       | MA-       | 9/43 (20.9)            | 6/43 (14)              |
| Males         | MA-       | 5/32 (15.6)            | 1/32 (3.1)             |
|               |           | RR                     | p                      |
| Female gender |           | 2.8 (1.6–5.1)          | 0.006                  |
| RLS           |           | 3.7 (1.9–7.1)          | 0.001                  |
| Gender and R  | LS        | 8.9 (3.6–22.0)         | < 0.0001               |

#### Inheritance of PFO & Migraine with Aura

- 71 relatives of 20 probands with a significant sized PFO or ASD on TEE
- Atrial shunt has AD inheritance
- Among proband with MWA,
  - 15 of 21 (71.4%) first relatives with atrial shunt had MWA, but 3 of 14 (21.4%) without shunt had MWA

### Migraine & PFO

#### Strong genetic association



#### Early report

# Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons

PT Wilmshurst, S Nightingale, K P Walsh, W L Morrison

Findings 37 of 40 consecutive patients who had had a closure procedure (to permit resumption of diving after decompression illness in 29, after stroke when paradoxical thromboembolism was suspected in four, or to close a large atrial septal defect in four) could be contacted. 21 (57%) had a history of migraine before the procedure (with aura in 16, without aura in five). 11 individuals had fortification spectra in the period immediately after closure. During long-term follow-up, no migraine symptoms were reported by seven individuals who had previously had migraine with aura and three who had previously had migraine without aura. Eight others who had had migraine with aura before closure reported improvement in frequency and severity of migraines. Three (one migraine with aura, two migraine without aura) reported no alteration in migraine episodes.

**Interpretation** These observations suggest a causal association between right-to-left shunts and migraine with aura. There may be a subgroup of patients who have severe migraine associated with a large right-to-left shunt in whom closure of the atrial defect may improve or abolish migraine.

Lancet 2000; 356: 1648-51

#### Clinical/Scientific Notes



#### Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine

Martijn C. Post, MD; Vincent Thijs, MD; Luc Herroelen, MD; and Werner I.H.L. Budts, MD, PhD

A patent foramen ovale (PFO) is one of the major causes of right-toleft shunt, and a causal relationship between migraine and a PFO has been suggested. We evaluated whether percutaneous closure of a PFO was associated with changes in the prevalence of migraine.

Methods. Patient selection. Patients with a PFO who had a paradoxical embolic event or systemic desaturation and who underwent a percutaneous closure in our center between February 1999 and September 2002 were included. The medical files were reviewed. The ethical committee approved the study.

Evaluation of migraine. A questionnaire was composed in such a way that a neurologist could diagnose migraine with or without aura (MA+ and MA-) according to the criteria of the International Headache Society. The questionnaire was sent to all patients and focused on three periods: 1 year before and 2 months and at least 6 months after percutaneous closure. Two neurologists blinded to the patients' files diagnosed MA+ and MA-.

Statistical analysis. Within-patient comparisons of the absence or presence of migraine were performed with the McNemar's paired  $\chi^2$  test. Interobserver reliability was evaluated by measuring the kappa coefficient. p Value < 0.05 was considered significant. All

Table Characteristics of patients who completed the auestionnaire

|  | Migraine  | No migraine | p      |
|--|-----------|-------------|--------|
| No. of patients (n)                            | 26        | 40          |        |
| Age (y, mean $\pm$ SD)                         | $55\pm10$ | $53\pm12$   | 0.48   |
| Male/female                                    | 9/17      | 27/13       | < 0.05 |
| Indication PFO closure                         |           |             |        |
| Stroke (n)                                     | 24        | 37          | 0.94   |
| Peripheral embolism (n)                        | 2         | 1           | 0.33   |
| Brain abscesses (n)                            | 0         | 1           |        |
| Desaturation (n)                               | 0         | 1           |        |
| Frequency of migraine attacks prior to closure |           |             |        |
| Almost monthly (n)                             | 9         |             |        |
| Almost weekly (n)                              | 9         |             |        |
| Several times a week (n)                       | 8         |             |        |

PFO = patent foramen ovale.

#### Mini-Focus: Transcatheter Closure of ASD and PFO

#### Association of Interatrial Shunts and Migraine Headaches

Impact of Transcatheter Closure

Babak Azarbal, MD, Jonathan Tobis, MD, William Suh, MD, Vicki Chan, BA, Catherine Dao, BA, Richard Gaster

Los Angeles, California

- Retrospective analysis
- Among 89 pt who underwent transcatheter closure of interatrial shunt
- 42% had migraine before procedure
- Migraine disappeared completely in 75% of MWA and 31% of MOA
- Remaining 40% had significant improvement

Vol. 45, No. 4, 2005 ISSN 0735-1097/05/\$30.00 doi:10.1016/j.jacc.2004.10.055

#### Migraine Headache Relief After Transcatheter Closure of Patent Foramen Ovale

Mark Reisman, MD,\* Ryan D. Christofferson, MD,\* Jill Jesurum, PhD,\* John V. Olsen, MD, FACC,\* Merrill P. Spencer, MD,† Kimberly A. Krabill, MD,\* Lance Diehl, MD,\* Sheena Aurora, MD,\* William A. Gray, MD\*

Seattle, Washington

- 162 pt performed transcatheter PFO closure in patients with paradoxical cerebral embolism
- Active migraine : 35% (57/162)
  - Complete resolution of migraine : 56% (28/50)
  - Significant reduction: 14%(7 of 50)
  - 80% reduction in the mean number of migraine episodes/mo


# Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting

Alessandro Giardini, MD,<sup>a</sup> Andrea Donti, MD,<sup>a</sup> Roberto Formigari, MD,<sup>a</sup> Luisa Salomone, MD,<sup>a</sup> Daniela Prandstraller, MD,<sup>a</sup> Marco Bonvicini, MD,<sup>a</sup> Gualtiero Palareti, MD,<sup>b</sup> Donata Guidetti, MD,<sup>c</sup> Oscar Gaddi, MD,<sup>d</sup> and Fernando Maria Picchio, MD<sup>a</sup> Bologna and Reggio Emilia, Italy

- 131 consecutive Pt with PFO closure due to cryptogenic stroke
- 35 (27%) had migraine
- 32 (91%) of 35 migraineurs had either complete resolution or significant improvement in headache

### **MIST Trial Design**

Multicenter, randomized, double-blind sham-controlled trial Migraine with aura : >5attacks/mo
Moderate or large right to left shunt due to PFO



#### Closure Makes No Difference

Table 3. Efficacy Analyses: Intention-to-Treat Population

|   | Implant (n=74) |                | Sham prod  | cedure (n=73)  | Statistical Analyses*                             |      |
|---|----------------|----------------|------------|----------------|---|------|
|   | Baseline       | Analysis Phase | Baseline   | Analysis Phase | Difference Between Implant and Sham Arms (95% CI) | Р    |
| Patients with no migraine attacks, n      | 0              | 3              | 1          | 3              | -0.06% (-6.45-6.34)                               | 1.0  |
| Frequency of migraine attacks/mo, mean±SD | 4.82±2.44      | 3.23±1.80      | 4.51 ±2.17 | 3.53±2.13      | 0.45 (-0.16-1.05)                                 | 0.14 |
| n   | 66             | 66             | 73         | 73             | •••   |      |
| Total MIDAS score, median (range)         | 36 (3-108)     | 17 (0-270)     | 34 (2-189) | 18 (0-240)     | 1 (-11-10)  | 0.88 |
| n   | 66             | 67             | 69         | 72             |   |      |
| Headache d/3 mo (MIDAS), median (range)   | 27 (0-70)      | 18 (0–90)      | 30 (5–80)  | 21 (0–80)      | 1 (-5-6)  | 0.79 |
| n   | 66             | 67             | 69         | 72             | •••   |      |
| HIT-6 total score, mean ±SD               | 67.2±4.7       | $59.5 \pm 9.3$ | 66.2±5.1   | $58.5 \pm 8.6$ | 0 (-3-2)  | 0.77 |
| n   | 67             | 67             | 69         | 73             | • • •   |      |

Missing data were replaced by last observation carried forward. Cl indicates confidence interval.

# Is migraine associated with right-to-left shunt a separate disease? Results of the SAM study

#### General characteristics of patients with SHUNT and NO SHUNT

|                          | No shunt (type 0–I) | Shunt (type II-III) | P     |
|--------------------------|---------------------|---------------------|-------|
| n                        | 265                 | 195                 |       |
| M/F                      | 65/200              | 41/154              | NS    |
| Age                      | 37.1 ± 11           | $34.1 \pm 10$       | 0.003 |
| Body mass index          | 23.01               | 22.43               | NS    |
| Migraine onset (age)     | 21 ± 11             | 19 ± 9              | NS    |
| FHx for migraine, yes/no | 173/87 (66%)        | 140/45 (76%)        | 0.045 |
| FHx for CVA, yes/no      | 105/153             | 81/102              | NS    |

# Is migraine associated with right-to-left shunt a separate disease? Results of the SAM study

Characteristics of migraine attacks in patients with SHUNT (type III) & NO SHUNT (type 0)

|                                    | No shunt (type 0) | Shunt (type III) | P     |
|------------------------------------|-------------------|------------------|-------|
| n                                  | 173               | 110              |       |
| M/F                                | 42/131            | 19/91            | NS    |
| Median aura duration, min          | 20                | 22               | NS    |
| Median aura complexity             | 2                 | 2                | NS    |
| Median pain severity (range 0-3)   | 3                 | 3                | NS    |
| Median n attacks overall*          | 27                | 18               | 0.014 |
| Median <i>n</i> without aura*      | 12                | 2                | 0.011 |
| Relative aura frequency percentage | 60                | 90               | 0.076 |

The SAM study suggests that the effect of RLS on migraine features is not relevant.

# White matter lesions in migraine & RLS: a conventional and diffusion MRI study

Presence of WMLs as detected by T2-weighted MRI and MRI-derived metrics in migraine patients without RILES and with RILES in migraine with aura

|                                       | Absence of RLS $n = 44$ | Presence of RLS $n = 36$ | <i>P</i> -value |
|---------------------------------------|-------------------------|--------------------------|-----------------|
| Absence of WMLs (number—%)            | 17–38.6                 | 14–38.9                  |                 |
| Presence of WMLs (number—%)           | 27–61.4                 | 22–61.1                  |                 |
| Number of WMLs (mean $\pm$ s.d.)      | $6.73 \pm 16.15$        | $2.39 \pm 3.83$          | 0.65*           |
| WML load (mm $^3$ ) (mean $\pm$ s.d.) | 228.74 ± 445.88         | 84.15 ± 153.05           | 0.41*           |
| No of DWI-hyperintense lesions        | 0                       | 0                        |                 |

RLS does not increase the likelihood of finding WMLs in migraineurs.

# White matter lesions in migraine & RLS: a conventional and diffusion MRI study

Vascular risk factors in migraine patients with T2-weighted MRI positive for the presence of WMLs vs. patients without MRI-detected lesions

|                              | Absence of WMLs  | Presence of WMLs | Dyalua          |
|------------------------------|------------------|------------------|-----------------|
|                              | n = 31           | n = 49           | <i>P</i> -value |
|                              | Number (%)       | Number (%)       |                 |
| Diabetes mellitus            | 0 (0)            | 1 (2)            | 0.99*           |
| Smoking                      | 8 (25.8)         | 13 (26.5)        | 0.99*           |
| Hypercholesterolaemia        | 2 (6.5)          | 7 (14.3)         | 0.47*           |
| Use of oral contraceptives   | 6 (19.4)         | 9 (18.4)         | 0.99*           |
| Family history of stroke/TIA | 1 (3.2)          | 3 (6.1)          | 0.99*           |
| Coagulation disorders        | 10 (32.2)        | 23 (46.9)        | 0.25*           |
| Body mass index, (kg/m²)     | $21.89 \pm 2.76$ | $22.22 \pm 3.06$ | 0.73†           |
| Age, mean $\pm$ s.d. (years) | $32.52 \pm 7.74$ | 39.93 ± 12.91    | 0.035†          |

### Migraine - PFO

- Does PFO cause migraine?
  - Strong association between migraine with aura and PFO
  - Circumstantial evidences
    - Higher prevalence of white matter lesions in migraine
    - Higher incidence of stroke in migraine
- Just Association due to Genetic Linkage?
  - Failure of clinical trial
  - Strong family history

### PFO - Ischemic Stroke

#### Can PFO Cause Ischemic Stroke?

- PFO
  - Potential source of paradoxical embolism
  - Prevalence of PFO in healthy: about 20%
- Guilty but Only as a Gang member
  - B Meier (JACC 2006:47:446-448)
  - Jus Sources with low or uncertain primary risk for ischemic stroke

Cardiac sources of embolism

<sup>a</sup>Mitral annular calcification<sup>92</sup>

<sup>b</sup>Patent foramen ovale<sup>93</sup>

Atrial septal aneurysm

Atrial septal aneurysm and patent foramen ovale Left ventricular aneurysm without thrombus

### **Cryptogenic Stroke**

 Approximately 30-40% of cerebral infarctions cannot be classified as strokes of determined cause despite a complete diagnostic work-up
 Sacco et al (Ann Neurol 1989)

- Cryptogenic stroke
  - Cerebral infarct due to some form of embolism
  - Failure to define a source of embolism
- Presence of PFO in cryptogenic stroke

# Relationship of Cryptogenic Stroke of with PFO among Young Patients

|           | N   | Age | PFO<br>(Cryptogenic) | PFO<br>(Control) | р      |
|-----------|-----|-----|----------------------|------------------|--------|
| Lechat    | 26  | <55 | 54%                  | 10%              | <0.001 |
| Webster   | 34  | <40 | 56%                  | 15%              | <0.001 |
| Cabanes   | 64  | <55 | 56%                  | 18%              | <0.001 |
| De Belder | 39  | <55 | 13%                  | 3%               | <0.001 |
| Di Tullio | 21  | <55 | 47%                  | 4%               | <0.001 |
| Hausmann  | 18  | <40 | 50%                  | 11%              | <0.001 |
| Total     | 202 |     | 46%                  | 11%(29/271)      | <0.001 |


# Relationship of Cryptogenic Stroke of with PFO among Old Patients

|           | N    | Age | PFO           | PFO         | р      |
|-----------|------|-----|---------------|-------------|--------|
|           |      |     | (Cryptogenic) | (Control)   |        |
| De Belder | 64   | >55 | 20%           | 5%          | <0.001 |
| Di Tullio | 2434 | >55 | 38%           | 8%          | <0.001 |
| Hausmann  | 20   | >40 | 15%           | 23%         | N.S    |
| Jones     | 57   | >55 | 18%           | 16%         | N.S.   |
| Total     | 165  |     | 21%           | 15%(61/414) |        |

| Characteristic                      | Cryptogenic Stroke<br>(N=227) | Stroke of Known Cause<br>(N = 276) | P Value |
|-------------------------------------|-------------------------------|------------------------------------|---------|
|                                     |                               |                                    |         |
| Female sex — no. (%)                | 94 (41.4)                     | 97 (35.1)                          | 0.17    |
| PFO — no. (%)                       | 77 (33.9)                     | 34 (12.3)                          | < 0.001 |
| PFO-ASA — no. (%)                   | 33 (14.5)                     | 11 (4.0)                           | < 0.001 |
| Hypertension — no. (%)              | 143 (63.0)                    | 222 (80.4)                         | < 0.001 |
| Diabetes — no. (%)                  | 48 (21.1)                     | 74 (26.8)                          | 0.15    |
| Hyperlipidemia — no. (%)            | 81 (35.7)                     | 111 (40.2)                         | 0.31    |
| History of smoking — no. (%)        | 68 (30.0)                     | 76 (27.5)                          | 0.55    |
| Coronary artery disease — no. (%)   | 41 (18.1)                     | 82 (29.7)                          | 0.003   |
| Peripheral artery disease — no. (%) | 12 (5.3)                      | 20 (7.2)                           | 0.46    |
| Aortic plaque — mm                  | 2.72±1.83                     | 3.06±1.55                          | < 0.001 |


<sup>\*</sup> Plus-minus values are means ±SD. PFO denotes patent foramen ovale, and ASA atrial septum aneurysm.

### **Define Causal Relationship**




#### **Recurrent Stroke with PFO & ASA**

Among 581 pt (18-55yo) with cryptogenic stroke



#### PFO in Cryptogenic Stroke Study (PICSS)

630 stroke patients with TEE randomly assigned into warfarin or aspirin group



On medical therapy, the presence of PFO in stroke pt did not increase the chance of event regardless of PFO size or ASA

#### Controversies in Stroke

Section Editors: Geoffrey A. Donnan, MD, FRACP, and Stephen M. Davis, MD, FRACP

#### Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes

Anthony J. Furlan, MD

#### Patent Foramen Ovale and Recurrent Stroke: Closure Is the Best Option: No

David C. Tong, MD; Kyra J. Becker, MD

### **Closure is Best Option: Yes**

- Warfarin is conventional medical therapy for PFO without hard evidences
- Warfarin carries 1% per year risk of significant hemorrhage
- Percutaneous PFO closure has a very low serious complication rate (<1%)</li>
- Long-term durability of devices is excellent
- Psychological aspect of the patients


### **Closure is Best Option: No**

There are no evidences for a relationship

betweer

Two stu
 not increase.

PFO is



### Time to Perform RCTs to Prove the Benefits of PFO Closure in Cryptogenic Stroke